RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer

Taylor, Douglas D.; Gerçel-Taylor, Çiçek

doi:10.1016/j.ygyno.2008.04.033

Cited by 2,174 publications

(1,850 citation statements)

References 29 publications

Supporting

Mentioning

1,745

Contrasting

Unclassified

Order By: Relevance

“…Similarly, miR-25 and miR-223 were reported as non-small cell lung cancer specific following their analysis in sera from 152 patients compared to 75 healthy volunteers [149]. Circulating miRNAs, albeit in exosomes, have also been reported to have potential as biomarkers for ovarian cancer [150] and for glioblastoma [78]. Studies of circulating miRNAs associated with breast cancer have been limited to date.…”

Section: Micrornas In Breast Cancermentioning

confidence: 99%

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

show abstract

Section: Micrornas In Breast Cancermentioning

confidence: 99%

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…[18][19][20] Tumor cellreleased exosomes are also detectable in the circulation where the plasma level of their specific proteins (eg, CD63 and tumor susceptibility gene 101/TSG101) and miRNA content may be useful as diagnostic and/or prognostic markers in different tumor types including colorectal carcinomas. [21][22][23][24] Our study was designed to analyze the top exosome-specific markers based on change of their tissue mRNA level during colorectal adenomacarcinoma sequence. For testing exosomes at the in situ protein level, we selected the ALG 2-interacting protein X (ALIX; also known as programmed cell death 6-interacting protein (PDCD6IP)), a multifunctional protein, which is involved in biogenesis of MVBs (as ESCRT I-III binding protein), lysosomal degradation and accumulates in exosomes.…”

mentioning

confidence: 99%

Exosomes in colorectal carcinoma formation: ALIX under the magnifying glass

et al. 2016

View full text Add to dashboard Cite

Exosomes are small membrane vesicles that have important roles in transporting a great variety of bioactive molecules between epithelial compartment and their microenvironment during tumor formation including colorectal adenoma-carcinoma sequence. We tested the mRNA expression of the top 25 exosome-related markers based on ExoCharta database in healthy (n = 49), adenoma (n = 49) and colorectal carcinoma (n = 49) patients using Affymetrix HGU133 Plus2.0 microarrays. Most related genes showed significantly elevated expression including PGK1, PKM, ANXA5, ENO1, HSP90AB1 and MSN during adenoma-carcinoma sequence. Surprisingly, the expression of ALIX (ALG 2-interacting protein X), involved in multivesicular body (MVB) and exosome formation, was significantly reduced in normal vs adenoma (P = 5.02 × 10 − 13 ) and in normal vs colorectal carcinoma comparisons (P = 1.51 × 10 − 10 ). ALIX also showed significant reduction (Po 0.05) at the in situ protein level in the epithelial compartment of adenoma (n = 35) and colorectal carcinoma (n = 37) patients compared with 27 healthy individuals. Furthermore, significantly reduced ALIX protein levels were accompanied by their gradual transition from diffuse cytoplasmic expression to granular signals, which fell into the 0.6-2 μm diameter size range of MVBs. These ALIX-positive particles were seen in the tumor nests, including tumorstroma border, which suggest their exosome function. MVB-like structures were also detected in tumor microenvironment including α-smooth muscle actin-positive stromal cells, budding off cancer cells in the tumor front as well as in cancer cells entrapped within lymphoid vessels. In conclusion, we determined the top aberrantly expressed exosome-associated markers and revealed the transition of diffuse ALIX protein signals into a MVB-like pattern during adenoma-carcinoma sequence. These tumor-associated particles seen both in the carcinoma and the surrounding microenvironment can potentially mediate epithelial-stromal interactions involved in the regulation of tumor growth, metastatic invasion and therapy response.

show abstract

“…In this respect, the EV concentration present in serum of tumor-bearing patients was shown to be increased compared to healthy controls [217,[232][233][234][235]. The EV protein abundance also has prognostic value as it was observed that patients with stage III melanoma with a high EV-associated TYRP2 protein burden showed increased risk of disease progression [207].…”

Section: 2evs As Biomarkermentioning

confidence: 97%

Therapeutic and diagnostic applications of extracellular vesicles

Stremersch

Smedt

Raemdonck

2016

Journal of Controlled Release

157

103

View full text Add to dashboard Cite

During the past two decades, extracellular vesicles (EVs) have been identified as important mediators of intercellular communication, enabling the functional transfer of bioactive molecules from one cell to another. Consequently, it is becoming increasingly clear that these vesicles are involved in many (patho)physiological processes, providing opportunities for therapeutic applications. Moreover, it is known that the molecular composition of EVs reflects the physiological status of the producing cell and tissue, rationalizing their exploitation as biomarkers in various diseases. In this review the composition, biogenesis and diversity of EVs is discussed in a therapeutic and diagnostic context. We describe emerging therapeutic applications, including the use of EVs as drug delivery vehicles and as cell-free vaccines, and reflect on future challenges for clinical translation. Finally, we discuss the use of EVs as a biomarker source and highlight recent studies and clinical successes.

show abstract

RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer

Cited by 2,174 publications

References 29 publications

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Exosomes in colorectal carcinoma formation: ALIX under the magnifying glass

Therapeutic and diagnostic applications of extracellular vesicles

Contact Info

Product

Resources

About